Last updated: August 25, 2026
CAPOZIDE 25/15 is a fixed-dose antihypertensive tablet containing captopril 25 mg and hydrochlorothiazide 15 mg. Its commercial position is weak because both active ingredients have been generic for decades, the combination has no meaningful remaining exclusivity, and the branded product is not a material revenue contributor in publicly reported manufacturer results. Current commercial value is concentrated in generic captopril/hydrochlorothiazide supply rather than in the CAPOZIDE brand.
What is CAPOZIDE 25/15?
CAPOZIDE 25/15 combines:
| Component |
Strength |
Pharmacologic role |
| Captopril |
25 mg |
Angiotensin-converting enzyme inhibitor |
| Hydrochlorothiazide |
15 mg |
Thiazide diuretic |
The product is an oral tablet indicated for hypertension when treatment with an angiotensin-converting enzyme inhibitor and a diuretic is clinically appropriate. The combination reduces pill burden but has limited differentiation from separately prescribed generic captopril and hydrochlorothiazide.
Captopril was one of the first commercially approved ACE inhibitors. Hydrochlorothiazide was already an established diuretic when CAPOZIDE entered the market. The product therefore competed primarily on combination convenience, dose selection, and physician familiarity rather than on novel pharmacology.
What is the FDA regulatory status of CAPOZIDE 25/15?
CAPOZIDE was approved as a prescription combination product, but its commercial status has declined substantially. FDA records distinguish between a product being discontinued for commercial reasons and a product being withdrawn for safety or efficacy concerns. The available regulatory record does not establish a safety-based withdrawal as the reason for the product’s decline.
The relevant regulatory characteristics are:
| Regulatory issue |
CAPOZIDE 25/15 position |
| Dosage form |
Immediate-release oral tablet |
| Active ingredients |
Captopril and hydrochlorothiazide |
| FDA pathway |
Original new drug approval followed by generic competition |
| Current branded commercial status |
Limited or discontinued market presence |
| Safety withdrawal finding |
No established safety-based withdrawal identified |
| Therapeutic category |
Hypertension |
| Biosimilar relevance |
None |
| Generic substitution |
High |
FDA’s Drugs@FDA database and product labeling provide the primary regulatory record for the branded product, while the Orange Book identifies approved products and current marketing status where listed.[1][2]
What patents protect CAPOZIDE 25/15?
No commercially significant patent protection remains for CAPOZIDE 25/15. The underlying intellectual-property estate consisted primarily of historical patents covering captopril, hydrochlorothiazide, and the fixed-dose combination. Those rights expired long before the current generic market.
Captopril patent position
Captopril was developed in the 1970s and commercialized before the modern wave of pharmaceutical patent litigation. The principal composition and use patents associated with early captopril products expired decades ago. Any patent term adjustment or patent-term-extension rights would not preserve exclusivity today.
Hydrochlorothiazide patent position
Hydrochlorothiazide is an old, extensively genericized diuretic. Its basic composition and therapeutic-use protection expired many years ago. The ingredient is available from numerous manufacturers and is also used in multiple fixed-dose antihypertensive combinations.
Combination-product protection
Historical combination patents may have covered the use of captopril with hydrochlorothiazide or particular dosage ratios. Those rights no longer create a blocking barrier for generic manufacturers. A current manufacturer could still hold process, packaging, or formulation rights, but those rights would not ordinarily prevent market entry for a conventional immediate-release tablet.
| Patent category |
Current commercial effect |
| Captopril composition patents |
Expired |
| Hydrochlorothiazide composition patents |
Expired |
| Historical combination patents |
Expired or commercially immaterial |
| New chemical entity exclusivity |
Expired |
| Pediatric exclusivity |
Not commercially relevant |
| Patent-term extension |
No remaining effect |
| Current formulation blocking patent |
No material barrier identified |
| Manufacturing know-how |
Limited; ingredients and dosage form are conventional |
When did CAPOZIDE 25/15 lose exclusivity?
CAPOZIDE lost meaningful exclusivity after the expiration of the historical patents covering captopril, hydrochlorothiazide, and the combination. The exact date depends on which patent and regulatory exclusivity period is used as the reference point, but the commercial loss of exclusivity occurred many years ago.
The product is now in the mature generic phase:
- Original branded launch and physician adoption.
- Entry by generic manufacturers after patent and regulatory exclusivity expiration.
- Rapid substitution toward lower-priced products.
- Declining brand prescriptions.
- Limited commercial relevance for the original sponsor.
CAPOZIDE is not comparable to a modern branded antihypertensive protected by a recent formulation patent or method-of-use patent. Its commercial lifecycle is effectively complete.
How many patents cover CAPOZIDE 25/15 today?
No publicly identified, unexpired patent appears to provide material exclusivity for the conventional CAPOZIDE 25/15 tablet. The practical answer is zero meaningful blocking patents.
This assessment concerns market access, not the possibility that a manufacturer could hold a narrow patent relating to a manufacturing step, impurity profile, tablet coating, packaging configuration, or analytical method. Such rights would not normally protect the active ingredient combination or prevent approval of a therapeutically equivalent generic product.
What is the Orange Book status of CAPOZIDE?
The FDA Orange Book is the main source for approved drug products, therapeutic-equivalence evaluations, and patent or exclusivity information submitted for listed products. CAPOZIDE’s commercial position is consistent with an old, genericized product rather than an actively protected branded medicine.
Key Orange Book implications include:
- No current branded patent estate capable of supporting a meaningful market exclusivity period.
- Generic competition based on abbreviated new drug applications.
- Therapeutic-equivalence analysis focused on the captopril/hydrochlorothiazide dosage form.
- Limited relevance of the original brand once multiple therapeutically equivalent products are available.
Orange Book status does not itself measure sales or market share. It establishes the regulatory and substitution framework, not the financial value of the product.[2]
What generic entry risks exist for CAPOZIDE 25/15?
Generic entry risk is effectively realized rather than prospective. Captopril/hydrochlorothiazide products can compete through:
- Abbreviated new drug applications.
- Authorized generic arrangements.
- Pharmacy substitution.
- Hospital and managed-care formularies.
- Contract manufacturing and distributor supply agreements.
The main barriers are operational rather than legal. A potential supplier must demonstrate pharmaceutical equivalence, bioequivalence, current good manufacturing practice compliance, reliable active pharmaceutical ingredient supply, and acceptable manufacturing economics.
The product’s 25 mg/15 mg strength may have a narrower commercial base than more commonly prescribed hydrochlorothiazide strengths, such as 12.5 mg or 25 mg. That can reduce the number of manufacturers willing to maintain inventory, but it does not create meaningful intellectual-property protection.
What formulations are protected by CAPOZIDE patents?
The commercially relevant CAPOZIDE product is an immediate-release tablet. There is no material evidence that an extended-release, abuse-deterrent, transdermal, injectable, or other differentiated delivery system protects the brand.
Potential technical issues for a generic manufacturer include:
- Content uniformity for low-dose hydrochlorothiazide.
- Stability of captopril, which is sensitive to moisture and oxidation.
- Tablet dissolution performance.
- Packaging that limits moisture exposure.
- Control of impurities and degradation products.
- Demonstration of bioequivalence for the fixed-dose product.
These are development and quality-control requirements, not durable exclusivity mechanisms. A manufacturer that solves them can compete without licensing the CAPOZIDE brand.
Does CAPOZIDE have method-of-use patent protection?
No commercially material method-of-use patent protection is apparent for the treatment of hypertension with captopril 25 mg and hydrochlorothiazide 15 mg. The use of ACE inhibitors and thiazide diuretics for hypertension is established medical practice, and any historical method patents would have expired.
Modern method-of-use patents can restrict labeling for a specific disease, patient population, dosing schedule, or clinical outcome. CAPOZIDE does not appear to have a current method-of-use strategy capable of supporting a protected market.
Which companies are challenging CAPOZIDE exclusivity?
The product is not subject to a meaningful current exclusivity challenge in the commercial sense. Generic manufacturers already compete in the relevant market. Because the underlying rights are expired, the competitive process does not depend on a high-profile Paragraph IV campaign against an active patent estate.
Potential competitors include manufacturers that produce captopril, hydrochlorothiazide, or other ACE inhibitor/thiazide combinations. The most significant competitive pressure also comes from substitute products, including:
- Lisinopril/hydrochlorothiazide.
- Enalapril/hydrochlorothiazide.
- Benazepril/hydrochlorothiazide.
- Losartan/hydrochlorothiazide.
- Valsartan/hydrochlorothiazide.
- Separate generic ACE inhibitor and diuretic prescriptions.
What Paragraph IV risks apply to CAPOZIDE 25/15?
Paragraph IV litigation is not a material current risk for CAPOZIDE because no economically important unexpired brand patent appears to block generic approval. Paragraph IV certifications are relevant when a generic applicant challenges a listed patent before expiration. That framework has little practical significance for a decades-old captopril/hydrochlorothiazide product with no current blocking estate.
Any future Paragraph IV dispute would more likely involve a newly developed formulation, a specific manufacturing process, or a different combination product rather than the conventional CAPOZIDE 25/15 tablet.
What patent litigation affects CAPOZIDE 25/15?
No significant active patent litigation involving CAPOZIDE 25/15 is apparent from the product’s mature generic status and absence of a current blocking patent estate. Historical disputes involving ACE inhibitors, diuretics, or generic approvals may provide legal background but do not materially alter the current market outlook.
The litigation risk profile is therefore low:
| Risk category |
Current assessment |
| Brand patent infringement |
Low |
| Paragraph IV litigation |
Low |
| Formulation litigation |
Low for conventional tablet |
| Manufacturing-process litigation |
Possible but narrow |
| ANDA approval challenge |
Low |
| Product-liability exposure |
Depends on ordinary pharmacovigilance and labeling |
| Antitrust or settlement risk |
Low |
Are there CAPOZIDE settlement agreements?
No commercially significant current settlement agreement is identified as controlling market entry for CAPOZIDE 25/15. A settlement would have mattered most during the period when branded patents remained unexpired and generic manufacturers sought earlier entry. That period has passed.
The absence of a current settlement barrier means market participation is determined by FDA approval, manufacturing economics, distributor access, and payer substitution rather than by a negotiated delayed-entry date.
What is the market size for CAPOZIDE 25/15?
A reliable current standalone market-size figure is not generally available in public company filings or FDA databases. Pharmaceutical companies typically report cardiovascular revenue at a portfolio or business-unit level and do not disclose sales for an old genericized product such as CAPOZIDE 25/15.
The addressable market is constrained by four factors:
- High generic substitution.
- Availability of competing ACE inhibitor/thiazide combinations.
- Declining use of captopril relative to longer-acting ACE inhibitors.
- Limited use of the exact 25 mg/15 mg strength.
The broader hypertension market remains large, but that does not translate into equivalent value for CAPOZIDE. The product competes in a low-price segment with limited brand loyalty and low switching costs.
What is the financial trajectory for CAPOZIDE 25/15?
CAPOZIDE’s financial trajectory is one of long-term erosion:
| Lifecycle phase |
Financial condition |
| Initial branded phase |
Premium pricing and sponsor-controlled distribution |
| Early generic phase |
Rapid price compression and prescription substitution |
| Mature generic phase |
Low unit economics and fragmented supply |
| Current position |
Limited branded revenue; commodity-like economics |
Bristol Myers Squibb’s public financial reporting does not identify CAPOZIDE as a standalone material revenue line. Its contribution is therefore not separately quantifiable from public filings. The brand’s economic value is likely limited to residual prescriptions, legacy demand, or isolated channel sales rather than a meaningful recurring revenue stream.[3]
Generic manufacturers can earn modest returns when they have low manufacturing costs, stable procurement, and efficient distribution. Those returns are vulnerable to price erosion, supply interruptions, and buyer concentration. The product is unlikely to support substantial investment in new clinical development or a large commercial sales force.
How strong is the CAPOZIDE patent estate?
The patent estate is commercially weak.
| Dimension |
Assessment |
| Composition protection |
Expired |
| Combination protection |
Expired |
| Method-of-use protection |
No material current protection identified |
| Formulation protection |
No material blocking protection identified |
| Geographic protection |
Limited to ordinary regulatory rights; no global exclusivity |
| Generic entry barrier |
Minimal |
| Licensing value |
Low |
| Litigation leverage |
Low |
The remaining value lies in regulatory know-how, manufacturing experience, trademarks, distribution relationships, and supply reliability. These assets can support a niche generic business but cannot recreate the historical branded franchise.
How does CAPOZIDE compare with newer antihypertensive combinations?
CAPOZIDE is disadvantaged against newer or more commonly used combinations.
| Product class |
Relative CAPOZIDE position |
| Captopril/hydrochlorothiazide |
Direct product category; mature and low priced |
| Lisinopril/hydrochlorothiazide |
Often stronger generic availability and longer dosing convenience |
| ARB/hydrochlorothiazide |
Alternative for patients who cannot tolerate ACE inhibitors |
| ACE inhibitor plus separate diuretic |
Flexible dosing and broad generic availability |
| Calcium-channel blocker combinations |
Different tolerability and prescribing profiles |
| Branded fixed-dose combinations |
May retain formulation or brand differentiation, unlike CAPOZIDE |
Captopril’s shorter duration of action can also make it less attractive than once-daily ACE inhibitors. Clinical choice depends on patient characteristics, tolerability, renal function, potassium levels, adherence, and prescribing practice, but the commercial trend favors broadly available once-daily generic combinations.
What licensing opportunities exist for CAPOZIDE?
The licensing value of the CAPOZIDE brand or underlying technology is low. A transaction could still involve:
- Regional trademark rights.
- Authorized generic distribution.
- Contract manufacturing.
- Legacy product portfolios.
- Supply rights in markets where the brand remains registered.
- Technology transfer for tablet manufacture.
A license would not provide meaningful patent exclusivity. Its value would depend on regulatory registrations, channel access, manufacturing cost, and local demand rather than on protected pricing.
What geographic coverage does CAPOZIDE have?
CAPOZIDE’s historical market coverage was broader than its current commercial relevance. Patent protection has expired in major pharmaceutical jurisdictions, including the United States and other mature markets. Any continuing sales are more likely to reflect local registrations, distributor activity, or legacy prescribing than exclusive rights.
Geographic risks include:
- Country-specific product discontinuation.
- Different generic-approval standards.
- Local price controls.
- Tender-based purchasing.
- Active pharmaceutical ingredient supply concentration.
- National substitution rules.
- Brand registration lapses.
The product should be assessed country by country. A continuing trademark registration in one jurisdiction does not establish patent exclusivity or a defensible premium price.
What manufacturing and intellectual-property barriers remain?
Manufacturing barriers are modest but real. Captopril requires attention to stability and impurity control, while the combination tablet must meet dissolution, content-uniformity, and bioequivalence requirements. Hydrochlorothiazide is widely available, and the tablet technology is conventional.
The principal barriers are:
- Reliable captopril API supply.
- Moisture-controlled manufacturing and packaging.
- FDA or national GMP compliance.
- Batch release testing.
- Commercial-scale economics.
- Distributor and pharmacy access.
These barriers can affect supply continuity, but they do not materially protect the original sponsor from competition.
Key Takeaways
- CAPOZIDE 25/15 contains captopril 25 mg and hydrochlorothiazide 15 mg.
- The product has no meaningful remaining patent or regulatory exclusivity.
- Generic entry is already established, making Paragraph IV litigation largely irrelevant.
- No material current formulation or method-of-use patent protection is identified.
- Standalone CAPOZIDE revenue is not disclosed in public manufacturer filings.
- The financial trajectory is long-term decline from branded product to low-value mature generic.
- Competitive pressure comes from generic captopril/hydrochlorothiazide, separate components, and newer antihypertensive combinations.
- Manufacturing and supply-chain execution matter more than intellectual property.
- Licensing value is limited to trademarks, registrations, distribution, and manufacturing arrangements.
FAQs
Is CAPOZIDE 25/15 still commercially available?
Availability depends on country, distributor, and manufacturer. The branded product has limited commercial presence, while equivalent captopril/hydrochlorothiazide products may remain available through generic channels.
What is the generic name for CAPOZIDE 25/15?
The generic name is captopril and hydrochlorothiazide tablets, with strengths of 25 mg and 15 mg, respectively.
Does CAPOZIDE 25/15 have biosimilar competition?
No. Biosimilars apply to biological products. CAPOZIDE is a small-molecule chemical drug and competes through conventional generic approval pathways.
Can a company launch a generic CAPOZIDE 25/15 without a license from Bristol Myers Squibb?
Generally, a company does not need a license to the expired CAPOZIDE patent estate to manufacture an approved therapeutically equivalent product. It cannot market the product using protected branding or misappropriate proprietary technology that remains legally protected.
Is CAPOZIDE 25/15 an attractive pharmaceutical acquisition target?
The product is unlikely to justify a standalone acquisition based on patent value. An acquisition could make commercial sense only as part of a broader mature-products portfolio with manufacturing, distribution, or regional registration value.
References
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
- Bristol Myers Squibb. (n.d.). Annual reports and SEC filings. https://www.bms.com/investors/annual-reports.html
- DailyMed. (n.d.). Captopril and hydrochlorothiazide tablet labeling. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/
- U.S. Food and Drug Administration. (1984). Approved product labeling for CAPOZIDE, captopril and hydrochlorothiazide tablets. FDA product-labeling records.
